RESUMO
Objective:To observe the efficacy and safety of the M receptor antagonist Bencycloquidium bromide nasal spray in treatment of seasonal allergic rhinitis with runny nose as the main symptom. Methods:From August 2021 to September 2021, 134 patients with seasonal allergic rhinitis were enrolled in the otolaryngology Outpatient Department of Peking University Third Hospital, First Affiliated Hospital of Harbin Medical University and China-Japanese Friendship Hospital of Jilin University, including 71 males and 63 females, with a median age of 38 years. TNSS score and visual analogue scaleï¼VASï¼ of total nasal symptoms were observed during 2 weeks of treatment with Bencycloquidium bromide nasal spray. Results:TNSS score decreased from ï¼8.89±3.31ï¼ on day 0 to ï¼3.71±2.51ï¼ on day 14ï¼P<0.001ï¼, VAS score of nasal symptoms decreased from ï¼24.86±7.40ï¼ on day 0 to ï¼6.84±5.94ï¼ on day 14ï¼P<0.001ï¼, VAS score of rhinorrhoea decreased from ï¼6.88±2.06ï¼ on day 0 to ï¼1.91±1.81ï¼ on day 14ï¼P<0.001ï¼. Rhinoconjunctivitis quality of life questionnaireï¼RQLQï¼ score decreased from ï¼94.63±33.35ï¼ on day 0 to ï¼44.95±32.28ï¼ on day 14ï¼P<0.001ï¼. The incidence of adverse reaction was low and no serious adverse events occurred during the whole experiment. Conclusion:Bencycloquidium bromide nasal spray has significant efficacy and good safety in the treatment of seasonal allergic rhinitis.